recommended reading

Study Points to Faster Acting Anthrax Vaccine

CDC

A new anthrax vaccine additive could help to guard people exposed to the lethal bacteria with fewer shots than a widely used formulation delivered in five doses over a year and a half, according to a new study made public on Friday.

Vaccine with the "CPG 7909" adjuvant prompted a stronger immune response in two doses than unaugmented treatment, according to the findings published in the journal Vaccine. Developers hope the research will yield a vaccine capable of conferring protection faster and in fewer injections to individuals exposed to anthrax, an agent long thought by experts to be a likely tool of bioterrorism.

The paper says scientists plan to further examine the additive's role in producing immune reactions and side effects, but it neither identifies a schedule for new research nor specifies whether the augmented vaccine might be administered outside "a post-exposure setting."

Each of four test groups received two "NuThrax" doses incorporating a different level of the experimental additive within the existing BioThrax vaccine. Additional subjects received either placebo shots or the standard version of BioThrax routinely administered to U.S. military personnel and held in the Strategic National Stockpile for general use in an anthrax outbreak.

Vaccinations incorporating any level of CPG 7909 produced stronger "toxin-neutralizing antibody responses" in two doses than vaccine without the adjuvant, but immune reactions evened out after four shots, according to the report. "Differences among the four [experimental vaccine] groups were not statistically significant," says an abstract of the report.

Immune responses from the augmented treatment reached their maximum after four weeks, seven days sooner than vaccine without the additive. However, recipients of the experimental vaccination also experienced temporary low counts of white blood cells involved in fighting infections, in part by helping to produce immune antibodies.

The "immunostimulatory" additive binds to a specific protein, setting off a chain reaction in the body's system for responding to disease threats.

The trial included 105 participants between 15 and 50 years old. No test subjects were exposed to anthrax in the study.

BioThrax manufacturer Emergent Biosolutions announced the start of a new phase 2 clinical study in January. The research team included experts from four other companies.

Threatwatch Alert

Thousands of cyber attacks occur each day

See the latest threats

JOIN THE DISCUSSION

Close [ x ] More from Nextgov
 
 

Thank you for subscribing to newsletters from Nextgov.com.
We think these reports might interest you:

  • Modernizing IT for Mission Success

    Surveying Federal and Defense Leaders on Priorities and Challenges at the Tactical Edge

    Download
  • Communicating Innovation in Federal Government

    Federal Government spending on ‘obsolete technology’ continues to increase. Supporting the twin pillars of improved digital service delivery for citizens on the one hand, and the increasingly optimized and flexible working practices for federal employees on the other, are neither easy nor inexpensive tasks. This whitepaper explores how federal agencies can leverage the value of existing agency technology assets while offering IT leaders the ability to implement the kind of employee productivity, citizen service improvements and security demanded by federal oversight.

    Download
  • Effective Ransomware Response

    This whitepaper provides an overview and understanding of ransomware and how to successfully combat it.

    Download
  • Forecasting Cloud's Future

    Conversations with Federal, State, and Local Technology Leaders on Cloud-Driven Digital Transformation

    Download
  • IT Transformation Trends: Flash Storage as a Strategic IT Asset

    MIT Technology Review: Flash Storage As a Strategic IT Asset For the first time in decades, IT leaders now consider all-flash storage as a strategic IT asset. IT has become a new operating model that enables self-service with high performance, density and resiliency. It also offers the self-service agility of the public cloud combined with the security, performance, and cost-effectiveness of a private cloud. Download this MIT Technology Review paper to learn more about how all-flash storage is transforming the data center.

    Download

When you download a report, your information may be shared with the underwriters of that document.